Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995

Graefes Arch Clin Exp Ophthalmol. 1998 Mar;236(3):164-73. doi: 10.1007/s004170050059.

Abstract

Purpose: We review the results of treatment of small to medium-sized choroidal malignant melanomas after high-dose-rate brachytherapy with a strontium-90 applicator.

Methods: The applicator is positioned against the sclera using an afterloading technique. Brachytherapy is completed in a single session lasting 2-4 h with the patient under local anaesthesia. From September 1983 until March 1995, 46 eyes were treated in this way. Most tumours were 7-11 mm in diameter (range from 4.5-15 mm) with a mean height of approximately 3 mm (range from 1.5-7 mm). Follow-up ranged from 6 months to 12 years (mean 49 months).

Results: Thirty of the 46 eyes had at the final evaluation a nonevolutive scar (20 of these after a single application, the others with some additional treatment). In 13 eyes the tumours were in involution but their complete destruction was not yet certain, and 3 eyes were enucleated for local recurrence. Three patients developed systemic metastases. No radiogenic complications were noticed.

Conclusion: Strontium-90 brachytherapy is a valuable and safe treatment technique for small to medium-sized choroidal malignant melanomas. In addition the use of a strontium-90 applicator is inexpensive thanks to this element's long half-life and the short application time.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brachytherapy*
  • Choroid Neoplasms / mortality
  • Choroid Neoplasms / pathology
  • Choroid Neoplasms / radiotherapy*
  • Eye Enucleation
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Male
  • Melanoma / mortality
  • Melanoma / pathology
  • Melanoma / radiotherapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Radiotherapy Dosage
  • Retrospective Studies
  • Strontium Radioisotopes / therapeutic use*
  • Survival Rate
  • Treatment Outcome

Substances

  • Strontium Radioisotopes